Slingshot members are tracking this event:

Post hoc subgroup analyses released of the Phase 3 MACE and SUSTAIN 6 studies evaluating Novo Nordisk's (NVO) OZEMPIC (semaglutide) in type 2 diabetics with high CV risk

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details The SUSTAIN 6 post-hoc analyses found that reduction in the risk of MACE was consistent in people at high cardiovascular risk treated with Ozempic® regardless of their cardiovascular risk profile at the start of the trial, including whether or not they had a prior heart attack or stroke, and whether they had cardiovascular risk factors or established cardiovascular disease. SUSTAIN 6 was a pre-approval cardiovascular outcomes trial in 3,297 people with type 2 diabetes and established cardiovascular disease or with at least one cardiovascular risk factor, compared to placebo, both in addition to standard of care.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 26, 2018
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3 Study, Mace, Sustain 6 Trial, Ozempic, Semaglutide, Diabetes